Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

PURPOSE: We hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway. The objectives of this phase I trial were to assess safety and biological activity of this combination. EXPERIMENTAL DESIGN...

Descripción completa

Detalles Bibliográficos
Autores principales: Falchook, Gerald S, Wheler, Jennifer J, Naing, Aung, Jackson, Edward F, Janku, Filip, Hong, David, Ng, Chaan S, Tannir, Nizar M, Lawhorn, Kristie N, Huang, Mei, Angelo, Laura S, Vishwamitra, Deeksha, Hess, Kenneth, Howard, Adrienne N, Parkhurst, Kristin L, Amin, Hesham M, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279372/
https://www.ncbi.nlm.nih.gov/pubmed/25373733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279372/
https://www.ncbi.nlm.nih.gov/pubmed/25373733

Ejemplares similares